newsfilter
← Latest News
GlobeNewswire·

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic